Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Indaptus Therapeutics, Inc. in our court records and SEC 8-K records (as of 2026-10-18).
- Leadership changes: the latest reported is Tim Ruan (Form 8-K filed 2026-09-04). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Sino Lion Ventures LTD (filed 2026-06-26).
Who is behind it
Indaptus Therapeutics, Inc.: incorporated in Delaware; business address in New York, New York; industry Pharmaceutical Preparations (Form D, 2026-09-04).
Officers and directors, each with the role and the filing that names them:
- Jeffrey A. Meckler: Executive Officer, Director (Form D, 2025-06-20)
- Michael J Newman: Executive Officer, Director (Form D, 2025-06-20)
- Nir Sassi: Executive Officer (Form D, 2025-06-20)
- Walt A. Linscott: Executive Officer (Form D, 2025-06-20)
- Roger J. Waltzman: Executive Officer (Form D, 2025-06-20)
- Roger J. Pomerantz: Director (Form D, 2025-06-20)
- Hila Karah: Director (Form D, 2025-06-20)
- Anthony J. Maddaluna: Director (Form D, 2025-06-20)
- William B. Hayes: Director (Form D, 2025-06-20)
- Mark J. Gilbert: Director (Form D, 2025-06-20)
- Robert E. Martell: Director (Form D, 2025-06-20)
| Report | Holder | Share |
|---|---|---|
| Schedule 13D/A, 2026-06-26 | Sino Lion Ventures LTD | 29.19% |
| Schedule 13D/A, 2026-06-26 | Yao Yun | 31.51% |
| Schedule 13D/A, 2026-06-26 | Dai Junyi | 8.44% |
| Schedule 13D/A, 2026-06-26 | Yang Ting | 8.44% |
| Schedule 13D/A, 2026-04-29 | Yao Yun | 37.1% |
| Schedule 13G/A, 2026-04-06 | Ya Ii Pn, LTD. | 0% |
| Schedule 13D, 2026-03-30 | Yao Yun | 37.8% |
| Schedule 13D/A, 2026-03-24 | Lazar David E. | 47.93% |
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-09-04 | Tim Ruan | departed | ||
| Form 8-K, 2026-06-05 | Walt A. Linscott | Chief Operating Officer | appointed | 2026-06-01 |
| Form 8-K, 2026-04-24 | Tim Ruan | Director | appointed | 2026-04-22 |
| Form 8-K, 2026-04-24 | Tim Ruan | appointed | ||
| Form 8-K, 2026-04-24 | Matthew McMurdo | Director | departed | |
| Form 8-K, 2026-04-23 | Tim Ruan | Director | appointed | 2026-04-22 |
| Form 8-K, 2026-04-23 | Tim Ruan | appointed | ||
| Form 8-K, 2026-04-23 | Matthew McMurdo | Director | departed | |
| Form 8-K, 2026-04-03 | Qinglai Lu | Director | appointed | 2026-04-08 |
Money raised
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2025-06-20 | $2.31M | $5M |
| Form D, 2025-01-22 | $2.25M | $2.25M |
| Form D, 2024-12-06 | $227K | $227K |
| Form D, 2024-08-22 | $205K | $205K |
Latest IPO step: Indaptus Therapeutics, Inc. amended its IPO registration (S-1/A, 2025-09-03).
IPO filings: S-1/A, 2025-09-03, S-1, 2025-09-02, S-1, 2025-02-12, S-1, 2024-12-23, S-1, 2024-09-12.
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
Permanent URL:
https://mentionfox.com/who-owns/indaptus-therapeuticsLast updated 2026-10-18
Primary record: Schedule 13D/A, 2026-06-26 · Form D, 2025-06-20 · Form 8-K, 2026-09-04 · Form 8-K, 2026-06-05
Who owns Indaptus Therapeutics, Inc.? Owners, funding and legal record. MentionFox, 2026-10-18. https://mentionfox.com/who-owns/indaptus-therapeutics